会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明申请
    • Diluent, methods of manufacture and use
    • 稀释剂,制造和使用方法
    • US20080193913A1
    • 2008-08-14
    • US12082376
    • 2008-04-10
    • John LynchAlan Weiss
    • John LynchAlan Weiss
    • A01N1/02
    • G01N33/54393
    • The use of diluent to reduce non-specific drug binding (NSB) provides a simple, flexible and biocompatible way to reduce chemical entity (such as drugs, drug candidates and other small molecules) NSB so that bioassay results may more closely predict the behavior of these compounds in vitro. Additionally, the use of diluent as the chemical entity diluent enhances the predictive nature of data emanating from high throughput drug assays such as Caco-2 drug transport assays, plasma protein drug binding assays, PAMPA assays, permeability assays, and drug solubility assays. The diluent is made by either filtering a selected plasma through an ultrafiltration membrane having nominal molecular weight cutoff of about 30 kD, preferably about 10 kD or below or by selectively adding individual components of a plasma or serum that do not contribute to non-specific binding.
    • 使用稀释剂来减少非特异性药物结合(NSB)提供了一种简单,灵活和生物相容的方法来减少化学实体(如药物,药物候选物和其他小分子)NSB,以便生物测定结果可以更加密切地预测 这些化合物在体外。 另外,使用稀释剂作为化学实体稀释剂增强了从高通量药物测定(例如Caco-2药物转运测定法,血浆蛋白质药物结合测定法,PAMPA测定法,渗透性测定法和药物溶解度测定)中发出的数据的预测性质。 稀释剂通过将选定的血浆过滤通过具有约30kD,优选约10kD或更低的标称分子量截留值的超滤膜或通过选择性加入不对非特异性结合有贡献的血浆或血清的各成分来制备 。
    • 14. 发明授权
    • Discrete event parallel simulation
    • 离散事件并行仿真
    • US07257526B1
    • 2007-08-14
    • US09543284
    • 2000-04-05
    • Boris Dmitrievich LubachevskyAlan Weiss
    • Boris Dmitrievich LubachevskyAlan Weiss
    • G06G17/50G06G17/10G06F9/46
    • G06F17/5009
    • An efficient parallel event simulation method is implemented by simulating blocks of M edge events, where M is approximately equal to e logeN, and N being the number of interconnected processing elements. Following a simulation iteration, each processing element shares information with adjacent processing elements that relates to events that the processing elements simulated which may affect the simulation of events at the neighbor processing elements. When the communication reveals that the information that is shared by a neighbor processing elements is different from the information that the processing element assumed, then the arriving information is kept and the simulation process is repeated. In executing the repeated simulations of a block, the same random variable values are employed. When all of the processing elements find that the arriving shared information is the same as the information already known to the receiving processing element, simulation of the block ends. A new simulation floor is ascertained, and another block of event is simulated.
    • 通过模拟M边缘事件的块来实现有效的并行事件模拟方法,其中M近似等于e log N,N是互连处理元件的数量。 在模拟迭代之后,每个处理元件与相关处理元件共享信息,这些处理元件涉及可以影响相邻处理元件上的事件的模拟的处理元件被模拟的事件。 当通信显示由相邻处理元件共享的信息与处理元件假设的信息不同时,保持到达的信息并重复模拟处理。 在执行块的重复模拟时,采用相同的随机变量值。 当所有处理元件发现到达的共享信息与接收处理元件已知的信息相同时,块的模拟结束。 确定了新的模拟层,并且模拟了另一块事件。
    • 17. 发明申请
    • Diluent, methods of manufacturing and use
    • 稀释剂,制造和使用方法
    • US20080044929A1
    • 2008-02-21
    • US11975768
    • 2007-10-22
    • John LynchAlan Weiss
    • John LynchAlan Weiss
    • G01N33/536
    • G01N33/54393
    • The use of diluent to reduce non-specific,drug binding (NSB) provides a simple, flexible and biocompatible way to reduce chemical entity (such as drugs, drug candidates and other small molecules) NSB so that bioassay results may more closely predict the behavior of these compounds in vitro. Additionally, the use of diluent as the chemical entity diluent enhances the predictive nature of data emanating from high throughput drug assays such as Caco-2 drug transport assays, plasma protein drug binding assays, PAMPA assays, permeability assays, and drug solubility assays. The diluent is made by either filtering a selected plasma through an ultrafiltration membrane having nominal molecular weight cutoff of about 30 kD, preferably about 10 kD or below or by selectively adding individual components of a plasma or serum that do not contribute to non-specific binding.
    • 使用稀释剂降低非特异性,药物结合(NSB)提供了一种简单,灵活和生物相容的方法来减少化学实体(如药物,药物候选物和其他小分子)NSB,以便生物测定结果可能更密切地预测行为 的这些化合物。 另外,使用稀释剂作为化学实体稀释剂增强了从高通量药物测定(例如Caco-2药物转运测定法,血浆蛋白质药物结合测定法,PAMPA测定法,渗透性测定法和药物溶解度测定)中发出的数据的预测性质。 稀释剂通过将选定的血浆过滤通过具有约30kD,优选约10kD或更低的标称分子量截留值的超滤膜或通过选择性加入不对非特异性结合有贡献的血浆或血清的各成分来制备 。
    • 20. 发明授权
    • Electric socket convertor
    • 电插座转换器
    • US5564943A
    • 1996-10-15
    • US451492
    • 1995-05-26
    • Alan Weiss
    • Alan Weiss
    • H01R31/06H01R33/05H01R33/00
    • H01R31/06H01R33/05
    • An electric socket convertor comprises a convertor plug receivable into a conventional electric light bulb socket. An electric convertor socket is connectable with a conventional electric cigarette lighter. A connecting mechanism electrically connects the convertor plug to the convertor socket, such that electric current at the conventional electric light bulb socket is conducted through the convertor plug to the convertor socket. An electric cigarette lighter is inserted into the convertor socket, and is thereby provided with a source of 12-volt D.C. Other portable electric devices similarly can be provided with 12-volt D.C. The electric socket convertor provides convenient access to 12-volt D.C. for numerous electrical devices, and obviates permanent electric socket installation.
    • 电插座转换器包括可接收到常规电灯泡插座中的转换器插头。 电动转换器插座可与常规电动点烟器连接。 连接机构将转换器插塞电连接到转换器插座,使得常规电灯泡插座处的电流通过转换器插头传导到转换器插座。 电动点烟器插入转换器插座,由此提供12伏直流电源其他便携式电气设备类似地可以提供12伏直流电插座转换器可方便地访问12伏直流电 电气设备,并避免永久性电插座安装。